Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions
A Bidikian, JP Bewersdorf, RM Shallis… - Expert Review of …, 2024 - Taylor & Francis
Introduction Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of
hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) …
hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) …